| Predicate |
Object |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-896
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K36-886
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-715
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-744
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-745
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-747
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K35-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-734
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-46
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-18 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-74
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-747
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P43-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-36
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-46 |
| filingDate |
2015-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate |
2017-06-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
JP-2017514862-A |
| titleOfInvention |
Chemotherapy adjuvant therapy for tumors, acquired immune deficiency syndrome and leukemia |
| abstract |
The present invention relates to a composition for use as an adjuvant therapy for anticancer chemotherapeutic agents, therapeutic agents for acquired immune deficiency syndrome and leukemia. The composition comprises Lactobacillus reuteri LRE03 strain DSM 23879 capable of potently stimulating the production of inflammatory cytokine (Th1) interferon (INF) -γ that exhibits significant antiviral and / or antibacterial activity, and / or Or a mixture comprising or preferably consisting of Lactobacillus salivarius LS06 strain DSM26037 capable of strongly stimulating the production of dendritic cells exhibiting significant antiviral and / or antibacterial activity. Further, the composition may comprise one or more of the following compounds: a bacterial strain capable of producing bacterial exopolysaccharide EPS when ingested; and / or tara gum plant polysaccharides such as gum); and / or highly biologically incorporated into Aloe arborescens gels; and / or gelling agents such as sodium alginate and / or intermittently sterilized bacterial cells Zinc available. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-7286592-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2021020896-A |
| priorityDate |
2014-05-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |